COVID-19 drug sales help boost Gilead 2nd-quarter results, HIV sales dip ...Middle East

Gilead Sciences Inc on Thursday posted higher-than-expected second-quarter earnings, helped by strong demand for its COVID-19 antiviral treatment, Veklury, but sales of its flagship HIV drugs lagged as the pandemic continued to limit visits to doctors. Gilead shares, which closed at $69.83, were down 2% in after hours trading.

Hence then, the article about covid 19 drug sales help boost gilead 2nd quarter results hiv sales dip was published today ( Friday 30/07/2021 - 12:46 AM ) and is available on Devdiscourse ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( COVID-19 drug sales help boost Gilead 2nd-quarter results, HIV sales dip )

Also on site :

• Tanker Hit: Oil Spill Threatens Oman Coastline
• There’s a novel solution to controversy over admission to New York City’s specialized high schools
• Middle East Conflicts Threaten India's Trade Routes